| University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry |
TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced positive results from its second collaborative study with the University of Delaware evaluating the efficacy of several formulations of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus. |
businesswire.com |
2025-05-06 21:54:00 |
Czytaj oryginał (ang.) |
| ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry |
TROY, Mich.--(BUSINESS WIRE)--ZIVO Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces plans for a second collaborative study with the University of Delaware. This new study aims to further explore the potential applications of ZIVO's proprietary active ingredients in mitigating the spread of Low Pathogenicity Avian Influenza (LPAI) virus a. |
businesswire.com |
2025-02-06 18:36:00 |
Czytaj oryginał (ang.) |
| ZIVO Bioscience to Present at The Microcap Conference 2025 |
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J. Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to di. |
businesswire.com |
2025-01-22 18:15:00 |
Czytaj oryginał (ang.) |
| ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities |
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today provided an update on activities related to licensing its product targeting coccidiosis in broiler chickens. Following the announcement in August 2024 of positive results from a 42-day coccidiosis study, the Company has been engaged in discussions. |
businesswire.com |
2024-12-23 10:00:00 |
Czytaj oryginał (ang.) |
| ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza |
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from a study conducted in collaboration with the University of Delaware that evaluated the potential of ZIVO's proprietary active ingredients to reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) virus among po. |
businesswire.com |
2024-12-20 11:29:00 |
Czytaj oryginał (ang.) |
| ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study |
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces additional findings from its 42-day coccidiosis challenge study that demonstrate the product's positive impact on the cost of broiler production as an alternative to commonly-used antibiotics. ZIVO's product candidate for use in pou. |
businesswire.com |
2024-02-07 18:54:00 |
Czytaj oryginał (ang.) |
| ZIVO Bioscience Announces Uplisting to OTCQB Market |
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces it has uplisted the trading of shares of its common stock from the OTC® Pink Market to the OTCQB® Venture Market (OTCQB), effective as of the opening of trading on Friday, January 26, 2024. Following this uplisting, ZIVO Bioscience. |
businesswire.com |
2024-01-29 10:00:00 |
Czytaj oryginał (ang.) |
| ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens |
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (OTC PINK: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive efficacy results following its recent 42-day coccidiosis challenge study further demonstrating the effectiveness of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO's product candidate for. |
businesswire.com |
2024-01-23 10:00:00 |
Czytaj oryginał (ang.) |
| ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens |
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day study to further validate the efficacy of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO is developing a product candidate for use in poultry feed that is designed to boos. |
businesswire.com |
2023-10-30 10:30:00 |
Czytaj oryginał (ang.) |
| ZIVO Bioscience Announces Reverse Stock Split |
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that the Board of Directors of the Company approved a 1-for-6 reverse stock split (the “Reverse Stock Split”) of its shares of common stock, par value $0.001 (the “Common Stock”) effective at 5:00 p.m. ET on October 26, 2023 (the “Effective. |
businesswire.com |
2023-10-26 12:30:00 |
Czytaj oryginał (ang.) |
| ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference |
BLOOMFIELD HILLS, Mich, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces that management will deliver a company presentation and will hold investor meetings at the 8 th Annual Dawson James Small Cap Growth Conference being held Thursday, October 12, 2023 at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Fla. |
globenewswire.com |
2023-10-03 12:30:00 |
Czytaj oryginał (ang.) |
| Trial Results Confirm Efficacy of ZIVO Bioscience's Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens |
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive results from a month-long coccidiosis trial in broiler chickens that was conducted by an independent veterinary research provider. The study evaluating the Company's novel immune-modulating biologic for treating coccidiosi. |
businesswire.com |
2023-09-19 20:15:00 |
Czytaj oryginał (ang.) |
| ZIVO Announces Commitment by ZWorldwide to Purchase all Zivolife™ Algal Biomass Product Produced Over the Next 18 Months |
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (“ZIVO” or the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today provided an update on the commercialization of Zivolife, its proprietary algal biomass as a food or food ingredient. Following strong initial sales, ZWorldwide, an independent distributor with exclusive rights to the Zivolife. |
businesswire.com |
2023-08-16 12:30:00 |
Czytaj oryginał (ang.) |
| ZIVO Commences Sales of its Proprietary Algal Biomass as Human Food |
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (“ZIVO” or the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the commercialization of its proprietary algal biomass as a food or food ingredient. ZIVO has engaged an independent distributor, ZWorldwide, Inc., who will launch the product, branded ZivolifeTM, with an initial focus on. |
businesswire.com |
2023-07-26 20:15:00 |
Czytaj oryginał (ang.) |
| ZIVO Stock: 6 Things to Know About Biotech ZIVO Bioscience as Shares Rocket on No News |
ZIVO Bioscience (ZIVO) stock is rocketing higher on Friday despite no news concerning the company in what appears to be a pump and dump. The post ZIVO Stock: 6 Things to Know About Biotech ZIVO Bioscience as Shares Rocket on No News appeared first on InvestorPlace. |
investorplace.com |
2021-09-24 15:04:03 |
Czytaj oryginał (ang.) |
| ZIVO Stock: Why It Substantially Increased Today |
The stock price of Zivo Bioscience Inc (NASDAQ: ZIVO) increased by over 90% during intraday trading this morning. This is why it happened. |
pulse2.com |
2021-09-24 14:07:11 |
Czytaj oryginał (ang.) |
| ZIVO Stock Price Surges Over 100% Pre-Market |
The stock price of Zivo Bioscience Inc (NASDAQ: ZIVO) increased by over 100% pre-market today. These are the details. |
pulse2.com |
2021-09-20 13:22:43 |
Czytaj oryginał (ang.) |
| Zivo Bioscience, Inc. Announces Pricing of Upsized $13.8 Million Public Offering and Up-listing to Nasdaq |
KEEGO HARBOR, Mich., May 27, 2021 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of nutritional/nutraceutical product candidates originally derived from proprietary algal cultures, today announced the pricing of its upsized underwritten public offering of 2,760,000 units at a price to the public of $5.00 per unit. Each unit to be issued in the offering consists of one share of common stock and one warrant to purchase one share of common stock at an exercise price of $5.50. The common stock and warrants are immediately separable and will be issued separately. The common stock and warrants are expected to begin trading on the Nasdaq Capital Market, on May 28, 2021, under the symbols “ZIVO” and “ZIVOW,” respectively. ZIVO expects to receive gross proceeds of $13.8 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In connection with the offering, the Company will effectuate a reverse split of its issued and outstanding common stock at a ratio of 1-for-80. The reverse stock split is expected to be effective at 12:01 a.m., Eastern Time, on May 28, 2021. The share numbers and pricing information in this release are adjusted to give effect to the reverse stock split. |
globenewswire.com |
2021-05-28 00:42:00 |
Czytaj oryginał (ang.) |
| ZIVO Bioscience Announces US Patent Office Notice of Allowance for Administration of Proprietary Algal Biomass to Support Immune Health |
KEEGO HARBOR, Mich., April 26, 2021 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of nutritional/nutraceutical product candidates originally derived from proprietary algal cultures, announces today the US Patent Office has issued a Notice of Allowance for the use of the company's proprietary algal biomass product to promote a healthy immune response for use in dairy cattle. Follow-on patent filings for other animal species and humans are in process. |
globenewswire.com |
2021-04-26 16:06:00 |
Czytaj oryginał (ang.) |
| ZIVO Bioscience to Participate in Maxim Group's Inaugural Emerging Growth Virtual Conference |
KEEGO HARBOR, Mich., March 11, 2021 (GLOBE NEWSWIRE) -- ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic and additive product candidates originally derived from proprietary algal cultures, announces that CEO Andrew A. Dahl will present at Maxim Group's Inaugural Emerging Growth Virtual Conference to be held March 17-18, 2021. |
globenewswire.com |
2021-03-11 14:25:00 |
Czytaj oryginał (ang.) |
| ZIVO Bioscience Successfully Confirms Poultry Growth Promotion and Feed Conversion Ratio Improvements in Typical Production Environments |
KEEGO HARBOR, MI / ACCESSWIRE / January 11, 2021 / ZIVO Bioscience, Inc. (OTCQB:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of therapeutic/additive product candidates originally derived from proprietary algal cultures, announces today that in its recent analysis of two poultry studies performed at separate research facilities, ZIVO product candidates provided statistically significant feed conversion benefits in healthy broiler flocks exposed to pathogens present in litter from previous flocks, emulating exposure that may occur in a typical broiler production environment. ZIVO has been developing a product candidate designed to boost immune response and combatting a broad range of infective pathogens, with the goal of improving feed conversion and productivity to provide cost-savings for poultry producers. |
accesswire.com |
2021-01-11 16:50:00 |
Czytaj oryginał (ang.) |